
ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $130.76 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 198.08%, resulting in a loss of $43.09 million. ACADIA Pharmaceuticals collected $131.61 million in revenue during Q3, but reported earnings showed a $14.46 million loss.